New Executive Leadership and CEO Announced for BiPar Sciences
- Atul Dhir, M.D., Ph.D. has been appointed new BiPar CEO to continue growing entrepreneurial and innovative culture -
- Hoyoung Huh, M.D., Ph.D. to take on broader role within sanofi-aventis organization -
BRIDGEWATER, N.J. and SOUTH SAN FRANCISCO, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its wholly-owned subsidiary, BiPar Sciences, today announced changes to the executive management team at BiPar Sciences.
BiPar Chief Executive Officer and President Hoyoung Huh, M.D., Ph.D. will take on a broader role in the sanofi-aventis organization as Chairman of the Board of Directors of BiPar, as well as chair of the newly formed BiPar Innovation Board. As part of this new role, Dr. Huh will serve as advisor to sanofi-aventis Chief Executive Officer Christopher A. Viehbacher and to Executive Vice President Research and Development Marc Cluzel, as well as to the Executive Committee, in the areas of innovation, R&D transformation, and entrepreneurship.
Sanofi-aventis has appointed Atul Dhir, M.D., Ph.D. as Chief Executive Officer of BiPar Sciences effective December 1, 2009. Dr. Dhir's mission is to continue developing the innovative BiPar portfolio, including the ongoing clinical program of BSI-201 - which, of an emerging class of investigational compounds (PARP inhibitors), is currently the furthest along in the Phase 3 clinical development in the metastatic triple negative breast cancer setting. As new Chief Executive Officer, Dr. Dhir will also be focused on maintaining the autonomy and entrepreneurial culture of BiPar, while capitalizing on the deep resources and experience of the worldwide sanofi-aventis organization.
Prior to joining BiPar, Dr. Dhir was a senior executive at US Oncology, one of the nation's largest cancer treatment and research networks. Previously, he had served as a vice president of the Healthcare Division of Monsanto and a consultant with McKinsey and Company.
About BiPar Sciences
BiPar Sciences is a biopharmaceutical organization dedicated to pioneering novel tumor-selective therapies designed to address urgent unmet needs of cancer patients. In addition to BSI-201, the company also has two additional compounds in preclinical development. BiPar Sciences, located in South San Francisco, California, is an independent, wholly-owned subsidiary of sanofi-aventis, Inc. For more information, please visit www.biparsciences.com.
Sanofi-aventis is a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York ( SNY).
Tel : +33 1 53 77 40 31
Mobile : +33 6 73 68 78 88
Tel: +1 908 981 5687
Mobile: +1 609 651 1323